LAKOMÝ, Radek, Martina LOJOVÁ, Lenka SOUČKOVÁ, Ludmila HYNKOVA, Katerina POLACHOVA, Jiri VASINA, Regina DEMLOVÁ, Alexandr POPRACH, Jiri SANA, Tomas PROCHAZKA, Martin SMRČKA, Pavel FADRUS, Radim JANCALEK, Iveta SELINGEROVÁ, Renata BELANOVA, Pavel SLAMPA, Petr POSPISIL and Tomáš KAZDA. 11C-methionine in the diagnostics and management of glioblastoma patients with rapid early progression: nonrandomized, open label, prospective clinical trial (GlioMET). BMC Cancer. LONDON: BMC, 2024, vol. 24, No 1, p. 1-16. ISSN 1471-2407. Available from: https://dx.doi.org/10.1186/s12885-024-12469-2.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name 11C-methionine in the diagnostics and management of glioblastoma patients with rapid early progression: nonrandomized, open label, prospective clinical trial (GlioMET)
Name in Czech 11C-methionine in the diagnostics and management of glioblastoma patients with rapid early progression: nonrandomized, open label, prospective clinical trial (GlioMET)
Authors LAKOMÝ, Radek (203 Czech Republic, guarantor, belonging to the institution), Martina LOJOVÁ (203 Czech Republic, belonging to the institution), Lenka SOUČKOVÁ (203 Czech Republic, belonging to the institution), Ludmila HYNKOVA, Katerina POLACHOVA, Jiri VASINA, Regina DEMLOVÁ (203 Czech Republic, belonging to the institution), Alexandr POPRACH, Jiri SANA, Tomas PROCHAZKA, Martin SMRČKA (203 Czech Republic), Pavel FADRUS, Radim JANCALEK, Iveta SELINGEROVÁ (203 Czech Republic), Renata BELANOVA, Pavel SLAMPA, Petr POSPISIL and Tomáš KAZDA (203 Czech Republic).
Edition BMC Cancer, LONDON, BMC, 2024, 1471-2407.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30230 Other clinical medicine subjects
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW GliMet
Impact factor Impact factor: 3.800 in 2022
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1186/s12885-024-12469-2
UT WoS 001249141700004
Keywords (in Czech) Glioblastoma; Rapid early progression; Radiopharmaceutical; C-11-methionine; Clinical trial; Positron emission tomography; Radiotherapy
Keywords in English Glioblastoma; Rapid early progression; Radiopharmaceutical; C-11-methionine; Clinical trial; Positron emission tomography; Radiotherapy
Tags Excelence Science, MOÚ, MU, user, článek v časopise
Tags International impact
Changed by Changed by: Bc. Hana Vladíková, BBA, učo 244692. Changed: 15/7/2024 15:38.
Abstract
Background Glioblastoma (GBM) is the most common and aggressive primary brain cancer. The treatment of GBM consists of a combination of surgery and subsequent oncological therapy, i.e., radiotherapy, chemotherapy, or their combination. If postoperative oncological therapy involves irradiation, magnetic resonance imaging (MRI) is used for radiotherapy treatment planning. Unfortunately, in some cases, a very early worsening (progression) or return (recurrence) of the disease is observed several weeks after the surgery and is called rapid early progression (REP). Radiotherapy planning is currently based on MRI for target volumes definitions in many radiotherapy facilities. However, patients with REP may benefit from targeting radiotherapy with other imaging modalities. The purpose of the presented clinical trial is to evaluate the utility of C-11-methionine in optimizing radiotherapy for glioblastoma patients with REP. Methods This study is a nonrandomized, open-label, parallel-setting, prospective, monocentric clinical trial. The main aim of this study was to refine the diagnosis in patients with GBM with REP and to optimize subsequent radiotherapy planning. Glioblastoma patients who develop REP within approximately 6 weeks after surgery will undergo C-11-methionine positron emission tomography (PET/CT) examinations. Target volumes for radiotherapy are defined using both standard planning T1-weighted contrast-enhanced MRI and PET/CT. The primary outcome is progression-free survival defined using RANO criteria and compared to a historical cohort with REP treated without PET/CT optimization of radiotherapy. Discussion PET is one of the most modern methods of molecular imaging. C-11-Methionine is an example of a radiolabelled (carbon 11) amino acid commonly used in the diagnosis of brain tumors and in the evaluation of response to treatment. Optimized radiotherapy may also have the potential to cover those regions with a high risk of subsequent progression, which would not be identified using standard-of-care MRI for radiotherapy planning. This is one of the first study focused on radiotherapy optimization for subgroup of patinets with REP.
Links
90249, large research infrastructuresName: CZECRIN IV
PrintDisplayed: 21/7/2024 01:31